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Inducing depletion through an apoptotic pathway or inhibiting B-cell proliferation and differentiation constitutes a rational approach to cure B-cell-mediated disorders. One such modality used recently in B-cell malignancies is rituximab, a B-cell-depleting monoclonal antibody against CD20. 2 Nevertheless, efforts to identify novel therapeutic targets remain essential.
Like NK, T and antigen-presenting cells, B cells express immunoreceptor tyrosine-based inhibitory motif bearing receptors such as the leukocyte immunoglobulin-like receptor LILRB1/ ILT2/CD85j. 3 ILT2 is characterized by a broad specificity for HLA class-I molecules, with the highest affinity for HLA-G. However, no information is currently available on the role of ILT2 and HLA-G in regulating neoplastic B-cell growth. The biological functions of HLA-G have been originally described in maternal-fetal tolerance and more recently in allograft acceptance and tumor escape showing evidences for its tolerogenic properties. 4 In contrast to classical HLA-class I, HLA-G is expressed in a limited number of healthy tissues and can be expressed as seven isoforms including four membrane-bound (HLA-G1 --HLA-G4) and three soluble (HLA-G5 --HLA-G7) proteins. 4 HLA-G expression in solid tumors has been well correlated to tumor escape and poor prognosis. However, enhanced HLA-G plasma levels in B-cell malignancies were not correlated with unfavourable clinical outcome. 4 Such discrepancies may be due to the nature of malignant cells, that is, immune cells expressing inhibitory receptors such as ILT2. In this context, one may hypothesize HLA-G to have an unexpected role as an inhibitor of neoplastic B-cell growth through ILT2 interaction.
To define the role of HLA-G/ILT2 interaction on malignant B cells, we used Burkitt lymphoma, MM and leukemia cell lines. These neoplastic B cell lines express ILT2, as shown for the Raji Burkitt lymphoma, taken as a representative example (Supplementary Figure 1a ). Because aggregation of HLA-G is critical for optimal interaction with ILTs, 5 experiments were carried out with HLA-G aggregated onto nanoparticles (that is, HLA-G). As control, we used nanoparticles processed in the same manner as for HLA-G nanoparticles but using an HLA-G-free source (that is, Ctrl). Results show that HLA-G strongly inhibited the proliferation of Raji cells in a dose-and time-dependent manner ( Figure 1a and Supplementary Figure 1b) . In parallel, we used a recombinant HLA-G protein unbound to magnetic particles and found that, although similar, its effects were less potent than aggregated HLA-G (data not shown). Using both siRNA and mAb approach to block ILT2 expression, we significantly reversed inhibition of Rajicell proliferation (Figures 1b and c and Supplementary Figure 1c) , demonstrating that HLA-G-mediated inhibition was driven through ILT2. Results were supported by experiments using plasma from volunteer donors (Saint-Louis Hospital, Paris, France) randomly obtained and sorted based on their HLA-G levels. Plasmas containing HLA-G at a concentration up to 75 ng/ml were considered as positive and used as a naturally produced HLA-G source (no. 1, 2 and 3, Figure 1d ) and those with a concentration o5 ng/ml were considered as negative (no. 4, 5, and 6, Figure 1e ). HLA-G þ plasma, but not HLA-G À , inhibited Rajicell proliferation as antibody-mediated neutralization of HLA-G from HLA-G þ plasma-enhanced Raji proliferation compared with controls (Figures 1d and e) .
To gain insights into the mechanisms underlying HLA-Gmediated inhibition, Raji cells were analyzed for cell-cycle progression and apoptosis. No significant increase of annexin-Vpositive and propidium iodide (PI)-negative apoptotic cells or double-positive annexin-V/PI necrotic cells and no mitochondrial membrane depolarization were observed with HLA-G-treated Raji cells (data not shown). In contrast, cell-cycle analysis in HLA-Gtreated Raji cells demonstrated an increase of cells in G0/G1 phase and a concomitant two-fold decrease of cells in S phase compared with controls ( Figure 1f and Supplementary Figure 1d) . This was confirmed by the reduced amounts of cyclin D1 in HLA-G-treated Raji cells (Figure 1g and Supplementary Figure 1e) , showing that HLA-G does not induce apoptosis or necrosis but rather a cell-cycle blockade. Such HLA-G-mediated cell-cycle inhibition was previously shown for erythroid progenitors and T cells.
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To identify the signaling cascades involved in HLA-G/ILT2-mediated inhibition of malignant B cells, we analyzed the STAT-, AKT/mTOR-and PKC-signaling pathways, which are frequently deregulated in B-cell disorders 6 ( Figure 1h and Supplementary  Figure 1f ). HLA-G/ILT2 interaction affected the STAT pathway in Raji cells in which the constitutive phosphorylation of STAT-3 (Tyr 705) and STAT-5 (Tyr 694) was decreased, whereas STAT-1 phosphorylation (Tyr 701) was not altered. Further analysis of the AKT/mTOR pathway showed that HLA-G decreased the constitutive phosphorylation of AKT at Ser473 but not at Thr308. HLA-G did not alter the phophorylation of upstream proteins such as PDK1 (Ser 241) and PTEN (Ser 380). Because AKT is phosphorylated at Thr308 by PDK1 and at Ser473 by mTORC2 formed by mTOR/Rictor complex, 7 HLA-G activity on AKT is mediated through mTOR. Accordingly, HLA-G decreased the constitutive phosphorylation level of Ser2481 and to a lesser extent of Ser2448 of mTOR. Interestingly, mTOR is phosphorylated at Ser2448 via the PI3 kinase/AKT-signaling pathway and autophosphorylated at Ser2481. Concurrently, mTOR protein levels decreased in Raji cells treated with HLA-G. The protein mTOR controls cell-fate decision through interactions with other proteins such as Raptor-and Rictor-forming functional complexes mTORC1 and mTORC2, respectively. Upon HLA-G treatment, Rictor protein level remained unchanged, whereas Raptor decreased. Because the overall levels of mTOR and Raptor decreased following 4-h engagement of HLA-G with ILT2, this decrease may be due to the intracellular degradation of mTOR and Raptor rather than a downmodulation of gene expression. Nevertheless, we cannot definitely state that HLA-G blocks directly mTORC1 as we did not investigate the phosphorylation levels of mTORC1 downstream targets, such as p70S6K and 4E-BP1. 8 We here show, nonetheless, that HLA-G clearly disturbed the mTOR-signaling pathway, a critical part of the cellular circuitry, which is often constitutively activated in tumor cells. 8 Supporting our data, a recent study has brought evidence that cell-cycle inhibition of activated T cells by HLA-G is mediated by phosphatase SHP-2 altering the mTOR pathway. 9 An essential function of AKT is to regulate cell metabolism and cell-cycle progression through phosphorylation and inactivation of GSK-3b, c-Raf, and Foxo proteins. We here observe that HLA-G decreased the phosphorylation of GSK-3b at Ser 9, c-Raf at Notably, PKCd-and PKCm-phosphorylated active forms have been described to negatively regulate B cells.
The above experiments showed that Raji used as a model for B lymphoma was susceptible to the inhibitory effects of HLA-G. We next investigated whether such susceptibility was a unique feature of Raji cells or rather a property shared with other malignant ILT2 þ B cell lines. To this end, the Burkitt lymphoma cell lines Daudi and Ramos, the MM cell lines OPM-2, LP1 and RPMI 8226 and the leukemia cell line BV173 were used. Similar cell-proliferation inhibition was observed with these malignant B cell lines (Figure 2a-f) . Remarkably, clinical evidence was provided by ex vivo analysis of bone marrow (BM) sample from MM patients whose CD138 À cells were impaired by 52%±15 (n ¼ 3) in their progression into CD138 þ myeloma cells by adding HLA-G in long-term cultures (Figures 2g and h ) when compared with those cultured in the absence of HLA-G (Ø and Ctrl). Of note, we previously described the production of soluble HLA-G proteins by BM-derived mesenchymal stem cells. ; mTOR Ser2448 and mTOR
Ser2481
; GSK-3b; c-Raf; Foxo1, Foxo3a and Foxo4; PKCa/bII; PKCd Ser643 and PKCd
Thr505
; and PKCm Ser744/748 and PKCm Ser916 was detected by immunoblot analysis with phosphospecific antibodies as indicated. Total protein level of AKT, mTOR, Raptor and Rictor was detected by immunoblot using specific antibodies. One representative experiment out of three is shown. Green and red arrows indicate decreased and increased phosphorylation, respectively.
We here demonstrate that HLA-G has a dual action by increasing levels of phosphorylation of PKC and decreasing those of AKT, mTOR, c-Raf, GSK3-b and Foxo proteins (Supplementary Figure 2) . All these effects converge to activate inhibitors or to inhibit activators of cell survival, growth and proliferation. We also demonstrate that proliferation of hematological tumor cells expressing ILT-2 receptor is inhibited by HLA-G, in contrast to solid tumors where HLA-G favors tumor escape 4 because solid tumor cells do not express receptor to HLA-G. Such unexpected antitumor effect of HLA-G was strengthened by ex vivo results showing that HLA-G may also impede the differentiation of CD45 þ CD138 À BM cells into malignant CD45 þ CD138 þ plasma cells, likely through a cytostatic mechanism such as a cell-cycle blockade at the G0/G1 phase as demonstrated with Raji cell line. As B-cell lymphoma and MM patients currently lack significant treatment options, our findings open promising therapeutic approach using HLA-G/ILT2 as antitumor agents in B-cell malignancies. Leukemia is a biologically heterogeneous hematological disease and has become one of the leading causes of cancer-related mortality worldwide. 1 Recent studies of the pathogenesis of leukemia have revealed that mutations and/or aberrant expression of specific protein tyrosine kinases, such as FMS-like tyrosine kinase 3 (FLT3) and Abl, are responsible for the development of several common types of leukemia. 2 --4 For example, activating mutations in FLT3 are found in approximately 1/3 of acute myeloid leukemia (AML) patients, with the most prevalent activating mutations being 'internal tandem duplications' (ITD) in the juxtamembrane domain.
5,6 Several large-scale studies have demonstrated that FLT3/ITD is strongly associated with leukocytosis and a poor prognosis.
7 --9 Thus, FLT3 is considered to be an important molecular target in the treatment of AML.
Despite many efforts in the past few years to develop FLT3 inhibitors for the treatment of AML, no FLT3 inhibitors have been approved for clinical use. Furthermore, except for a small number of inhibitors (such as AC220), most of the known FLT3 inhibitors that are currently in clinical trials do not show impressive clinical efficacy.
10 --12 These facts imply a requirement to develop new-generation FLT3 inhibitors with improved clinical efficacy, especially novel multikinase inhibitors because they are thought to enhance the therapeutic effect of FLT3 inhibitors in AML.
13 Under these circumstances, we recently discovered a novel multikinase inhibitor termed SKLB1028 (Figure 1a) . In this letter, we report the preclinical efficacy of SKLB1028 in AML; a brief description regarding the chemical characterization of SKLB1028 is provided in the Supplementary Material. SKLB1028 also showed considerable potency in models of chronic myeloid leukemia (CML) that harbor Abl mutants, which will also be reported here.
The kinase-inhibition profile of SKLB1028 against a panel of recombinant human protein kinases was measured by the 'gold standard' radiometric kinase assay approach, and the results are shown in Supplementary Table S1 . SKLB1028 potently inhibited the wild-type and L858R-mutant EGFR with half-maximal inhibitory concentration (IC 50 ) values of 0.031 and 0.004 mM, respectively. The IC 50 values of SKLB1028 against FLT3 (Figure 1b) and Abl were 0.055 and 0.081 mM, respectively. Of note, this compound also inhibited the Abl-T315I mutant with considerable potency (IC 50 : 0.071 mM); this AblT315I mutant is associated with imatinib resistance. Furthermore, SKLB1028 inhibited FYN, HCK, KDR, PDGFRb, CSF1R, FGFR1 and FGFR2 with moderate activity (the IC 50 values were 0.214, 0.487, 0.330, 0.360, 1.040, 1.20 and 0.980 mM, respectively). SKLB1028 displayed negligible inhibitory activity against the 24 additional protein kinases that were tested. These data demonstrate that SKLB1028 is a multikinase inhibitor with high potency against EGFR, FLT3 and Abl and has good kinase-spectrum selectivity.
The growth-inhibitory potencies of SKLB1028 against various leukemia cell lines as well as several other cell lines were examined using the MTT assay method, and the results are presented in Supplementary Table S2 . SKLB1028 potently inhibited the growth of MV4-11 cells that express FLT3-ITD, with an IC 50 value of 0.002 mM (Figure 1c ), but moderately inhibited the proliferation of RS4-11 cells that express wt-FLT3, with an observed IC 50 of 0.790 mM. SKLB1028 also potently inhibited the growth of Ba/F3 cells that stably express human FLT3ITD (Ba/F3-FLT3-ITD), with an IC 50 of 0.01 mM, but was nontoxic toward parental Ba/F3 cells at concentrations up to 5 mM. SKLB1028 inhibited the cell growth of K562 cells that express the Bcr-Abl mutant with an IC 50 of 0.190 mM. SKLB1028 exhibited only a weak inhibitory potency in the human leukemia cell lines SU-DHL-6, TF-1, Karpas299 and Jurkat. Finally, SKLB1028 at a concentration of 10 mM did not inhibit the growth of the human myeloma cell line RPMI8226, human normal cell line LO2 and Chinese hamster ovary cell line CHO (Supplementary Table S2 ).
The ability of SKLB1028 to inhibit the activation of FLT3 and downstream signaling proteins in intact cells was assessed using western blot analysis. As shown in Figure 1d , SKLB1028 inhibited FLT3 phosphorylation in a dose-dependent manner. Consistent with the downregulation of the phosphorylation of FLT3, the phosphorylation of the downstream signaling proteins STAT5 and ERK1/2 was also significantly inhibited at concentrations 40.003 mM (Figure 1e ). We further examined the influence of SKLB1028 treatment on the cell cycle of MV4-11 cells using flow cytometry, and the results indicated that SKLB1028 could induce cell cycle arrest in G1 phase (Supplementary Figure S1) . By observing the morphological changes in the nuclei using Hoechst staining, we found that the nuclei of SKLB1028-treated MV4-11 cells shrank, became rounded up, and eventually divided into several apoptotic bodies (Supplementary Figure S2) , indicating Accepted article preview online 9 March 2012; advance online publication, 3 April 2012;
